Baylor Akhavan on Muck Rack

Baylor Akhavan

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Baylor

Contact Baylor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evaluation of Prognostic Markers for Progression-Free Survival of Metastatic Melanoma Patients Treated with First-Line Ipilimumab Plus Nivolumab

|
By Wolfram Samlowski, Baylor Akhavan
| preprints.org
This version is not peer-reviewed. Baylor Akhavan,Wolfram Samlowski  * Baylor Akhavan,Wolfram Samlowski  * Submitted: 03 September 2025 Posted: 03 September 2025 You are already at the latest version Background: Combination checkpoint inhibitor therapy with ipilimumab plus nivolumab has significantly improved the treatment of patients with metastatic melanoma. This regimen has induced durable complete remissions and improved survival.
Open in Who Shared Issue with article?
See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Baylor

Contact Baylor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified